Dr. Townsley on Screening for GATA2 in At-Risk Patients for MDS, AA, and AML

Danielle Townsley, MD
Published: Wednesday, May 06, 2015



Danielle Townsley, MD, staff clinician, Cell Biology Section, National Institutes of Health, discusses screening for GATA2 in patients who are at risk for myelodysplastic syndromes (MDS), aplastic anemia (AA), and acute myeloid leukemia (AML).

Through a collaboration of National Institutes of Health research teams, a study was conducted which found that patients with a family history of MDS, AA, and AML need or require screening for GATA2, a gene that, when mutated, often leads to these diseases. GATA2 controls the production of blood, Townsley explains. When it is impaired, bone marrow disorders can occur.

It can be difficult to distinguish a patient with a GATA2 deficiency that is related to MDS, because some patients do not have a strong family history of these diseases. Also, some patients may not have key physical exam findings, Townsley adds.



Danielle Townsley, MD, staff clinician, Cell Biology Section, National Institutes of Health, discusses screening for GATA2 in patients who are at risk for myelodysplastic syndromes (MDS), aplastic anemia (AA), and acute myeloid leukemia (AML).

Through a collaboration of National Institutes of Health research teams, a study was conducted which found that patients with a family history of MDS, AA, and AML need or require screening for GATA2, a gene that, when mutated, often leads to these diseases. GATA2 controls the production of blood, Townsley explains. When it is impaired, bone marrow disorders can occur.

It can be difficult to distinguish a patient with a GATA2 deficiency that is related to MDS, because some patients do not have a strong family history of these diseases. Also, some patients may not have key physical exam findings, Townsley adds.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x